Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Enveric Biosciences, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +1 vs. Q2 2023
- Shares held
- 222.9K
- +35.6K (+19.0%) vs. Q2 2023
- Total value
- $518.3K
- −$112.7K (−17.9%) vs. Q2 2023
- New holders
- 4
- 5 more added
- Sold out
- 3
- 1 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $736.8K |
| Q1 2026 | 11 | $106.6K |
| Q4 2025 | 11 | $87.7K |
| Q3 2025 | 11 | $232.6K |
| Q2 2025 | 14 | $283.2K |
| Q1 2025 | 15 | $344.7K |
| Q4 2024 | 19 | $386.7K |
| Q3 2024 | 17 | $337.2K |
| Q2 2024 | 17 | $307.3K |
| Q1 2024 | 18 | $488.4K |
| Q4 2023 | 15 | $635.8K |
| Q3 2023 | 15 | $518.3K |
| Q2 2023 | 14 | $631.1K |
| Q1 2023 | 13 | $382.4K |
| Q4 2022 | 12 | $356.8K |
| Q3 2022 | 12 | $623.0K |
| Q2 2022 | 27 | $1.99M |
| Q1 2022 | 31 | $3.61M |
| Q4 2021 | 31 | $4.45M |
| Q3 2021 | 24 | $4.64M |
| Q2 2021 | 18 | $2.72M |
| Q1 2021 | 14 | $3.42M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Enveric Biosciences, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AdvisorShares Investments LLC | 146,833 | $339.2K | 0.09% | +46,404+46.2% | Added |
| BlackRock Inc. | 29,578 | $70.4K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 18,015 | $42.9K | 0.00% | +5,500+43.9% | Added |
| Geode Capital Management, LLC | 13,118 | $30.3K | 0.00% | +13,118 | New |
| Tower Research Capital LLC (TRC) | 9,621 | $22.9K | 0.00% | +1,294+15.5% | Added |
| Acadian Asset Management LLC | 4,559 | $10.0K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 311 | $740 | 0.00% | +257+475.9% | Added |
| Advisor Group Holdings, Inc. | 300 | $714 | 0.00% | +300 | New |
| Group One Trading, L.P. | 273 | $631 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 100 | $238 | 0.00% | −1−1.0% | Reduced |
| National Bank of Canada | 70 | $157 | 0.00% | 00.0% | Unchanged |
| Toronto Dominion Bank | 54 | $129 | 0.00% | +54 | New |
| Wells Fargo & Company | 34 | $81 | 0.00% | +4+13.3% | Added |
| Morgan Stanley | 1 | $2 | 0.00% | 00.0% | Unchanged |
| Highlander Capital Management, LLC | 1 | $0 | 0.00% | +1 | New |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −17,170−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −13,933−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −228−100.0% | Sold out |